Targeting Cutaneous Cannabinoid Signaling in Inflammation: A Highway to Heal?
January 2017
in “
EBioMedicine
”
New to cannabidiol? There is a guide in the encyclopedia. Read the guide → Studysummary This study discusses potential anti-inflammatory roles of endocannabinoid system modulation and phytocannabinoids in skin health, but reports no new clinical results; the authors emphasize the need for further clinical exploration.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The study explored the role of the endocannabinoid system (ECS) in regulating skin inflammation, highlighting the potential of targeting cutaneous cannabinoid signaling for therapeutic purposes. It was found that the ECS, through CB1 and CB2 receptors, played a crucial role in maintaining skin homeostasis and controlling inflammation. In particular, inhibiting the enzyme FAAH, which degrades endocannabinoids, could restore anti-inflammatory signaling and alleviate skin inflammation. Additionally, non-psychotropic phytocannabinoids like cannabidiol (CBD) showed promise in managing acne by normalizing lipid production and exerting anti-inflammatory effects. These findings suggested that both FAAH inhibitors and phytocannabinoids could be promising candidates for developing new anti-inflammatory treatments for skin conditions.
